- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab: A Review of Its Use in Advanced Cancer
Authors
Keywords
Overall Survival, Paclitaxel, Bevacizumab, Objective Response Rate, Pemetrexed
Journal
DRUGS
Volume 74, Issue 16, Pages 1891-1925
Publisher
Springer Nature
Online
2014-10-14
DOI
10.1007/s40265-014-0302-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
- (2017) A. J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
- (2017) Ralph Zinner et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.
- (2017) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer
- (2016) Shubham Pant et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Incidence and Relevance of Proteinuria in Bevacizumab-Treated Patients: Pooled Analysis from Randomized Controlled Trials
- (2014) Richard A. Lafayette et al. AMERICAN JOURNAL OF NEPHROLOGY
- Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
- (2014) Sanne de Haas et al. ANGIOGENESIS
- Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
- (2014) F. Barlesi et al. ANNALS OF ONCOLOGY
- Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44)
- (2014) Bernd Gerber et al. ANNALS OF SURGICAL ONCOLOGY
- Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
- (2014) Tomas Buchler et al. BMC CANCER
- Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
- (2014) Lubomir Slavicek et al. BMC GASTROENTEROLOGY
- A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
- (2014) Antonio Llombart-Cussac et al. BREAST
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
- (2014) B P Schneider et al. BRITISH JOURNAL OF CANCER
- Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
- (2014) DJ Slamon et al. CANCER RESEARCH
- Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer
- (2014) A Schneeweiss et al. CANCER RESEARCH
- Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer
- (2014) James J. Lee et al. Clinical Colorectal Cancer
- Optimal duration of systemic treatment in metastatic colorectal cancer
- (2014) Lieke H.J. Simkens et al. CURRENT OPINION IN ONCOLOGY
- Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
- (2014) Katrina N. Slaughter et al. GYNECOLOGIC ONCOLOGY
- Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer
- (2014) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer
- (2014) Darshan A. Mehta et al. GYNECOLOGIC ONCOLOGY
- Current management and future perspectives of metastatic renal cell carcinoma
- (2014) Richard Lee-Ying et al. INTERNATIONAL JOURNAL OF UROLOGY
- Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
- (2014) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
- (2014) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
- (2014) Robert A. Burger et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study
- (2014) Thomas J. Lynch et al. Journal of Thoracic Oncology
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Bevacizumab in Treatment of High-Risk Ovarian Cancer--A Cost-Effectiveness Analysis
- (2014) J. K. Chan et al. ONCOLOGIST
- Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer
- (2014) Byeong Seok Sohn et al. ONCOLOGY
- Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
- (2014) Axel Grothey et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Immunologics and Chemotherapeutics for Renal Cell Carcinoma
- (2014) Elan Diamond et al. SEMINARS IN INTERVENTIONAL RADIOLOGY
- Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
- (2013) B. J. Monk et al. ANNALS OF ONCOLOGY
- A multinational phase II trial of bevacizumab with low-dose interferon- 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
- (2013) B. Melichar et al. ANNALS OF ONCOLOGY
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
- (2013) B. Gerber et al. ANNALS OF ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) J. A. Ledermann et al. ANNALS OF ONCOLOGY
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer
- (2013) Jason C. Barnett et al. CANCER
- Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma
- (2013) Susan Halabi et al. CANCER
- CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
- (2013) Yukiya Narita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
- (2013) Matthew D. Hellmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
- (2013) F. Collinson et al. CLINICAL CANCER RESEARCH
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
- (2013) B. P. Schneider et al. CLINICAL CANCER RESEARCH
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- (2013) D. Maru et al. CLINICAL CANCER RESEARCH
- Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
- (2013) Bernard Escudier et al. DRUGS
- The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study
- (2013) Hannah E. Carter et al. EUROPEAN JOURNAL OF CANCER
- Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab
- (2013) L. Randall et al. GYNECOLOGIC ONCOLOGY
- Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer
- (2013) Robert. A. Burger et al. GYNECOLOGIC ONCOLOGY
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Jyoti D. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
- (2013) Fabrice Barlesi et al. JOURNAL OF CLINICAL ONCOLOGY
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
- (2013) Dan Stark et al. LANCET ONCOLOGY
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
- (2013) Istvan Lang et al. LANCET ONCOLOGY
- Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
- (2013) Yasuhide Yamada et al. LANCET ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies
- (2013) H. I. Hurwitz et al. ONCOLOGIST
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) S. Peters et al. ANNALS OF ONCOLOGY
- Genitourinary tumors, non-prostate
- (2012) A. Ravaud et al. ANNALS OF ONCOLOGY
- Evidence-based role of bevacizumab in non-small cell lung cancer
- (2012) E. E. Vokes et al. ANNALS OF ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) B. Escudier et al. ANNALS OF ONCOLOGY
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) F. Cardoso et al. ANNALS OF ONCOLOGY
- XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
- (2012) Dimitrios Pectasides et al. BMC CANCER
- Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination and survival of ovarian carcinoma xenograft models
- (2012) P Oliva et al. BRITISH JOURNAL OF CANCER
- Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon
- (2012) Jing Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
- (2012) I. Lang et al. EUROPEAN JOURNAL OF CANCER
- Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study
- (2012) Fairooz F. Kabbinavar et al. EUROPEAN JOURNAL OF CANCER
- Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study
- (2012) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer
- (2012) Mariangela Manzoni et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
- (2012) Jeffrey A. Meyerhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
- (2012) E. Diaz-Rubio et al. ONCOLOGIST
- Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
- (2012) J. C. Bendell et al. ONCOLOGIST
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers
- (2012) Taher Abu-Hejleh et al. Current Oncology Reports
- Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
- (2012) Zhong-Zhen Guan et al. Chinese Journal of Cancer
- Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab †
- (2011) D. Malka et al. ANNALS OF ONCOLOGY
- Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- Bevacizumab-Induced Hypertension
- (2011) Kostas N. Syrigos et al. BIODRUGS
- A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
- (2011) Alberto J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)
- (2011) David Cella et al. BREAST CANCER RESEARCH AND TREATMENT
- Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial
- (2011) Ian Smith et al. BREAST CANCER RESEARCH AND TREATMENT
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
- (2011) Alfonso De Stefano et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
- (2011) Jianguo Zhi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
- (2011) Javier Cortés et al. EUROPEAN JOURNAL OF CANCER
- Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
- (2011) Xiao Feng Hang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Bevacizumab Treatment for Solid Tumors
- (2011) Daniel F. Hayes JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bevacizumab and Heart Failure Risk in Patients With Breast Cancer: A Thorn in the Side?
- (2011) Nitin Verma et al. JOURNAL OF CLINICAL ONCOLOGY
- At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
- (2011) David E. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab
- (2011) Yuan-Yuan Zhao et al. Journal of Thoracic Oncology
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy
- (2011) She-Juan An et al. MEDICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
- (2010) I. E. Smith et al. ANNALS OF ONCOLOGY
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
- (2010) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Clinical Utility of Routine Proteinuria Evaluation in Treatment Decisions of Patients Receiving Bevacizumab for Metastatic Solid Tumors
- (2010) J. Yeh et al. ANNALS OF PHARMACOTHERAPY
- Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
- (2010) A Abajo et al. BRITISH JOURNAL OF CANCER
- Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
- (2010) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data
- (2010) David F. McDermott et al. CANCER TREATMENT REVIEWS
- Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
- (2010) Maria Di Bartolomeo et al. DRUGS & AGING
- Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
- (2010) Mao Mao An et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
- (2010) M.P. Smerdel et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab toxicities and their management in ovarian cancer
- (2010) Leslie M. Randall et al. GYNECOLOGIC ONCOLOGY
- Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
- (2010) D.L. Richardson et al. GYNECOLOGIC ONCOLOGY
- Clinical predictors of bevacizumab-associated gastrointestinal perforation
- (2010) Janos L. Tanyi et al. GYNECOLOGIC ONCOLOGY
- Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab
- (2010) Vincenzo Formica et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
- (2010) Suzanne E. Dahlberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599
- (2010) Julie R. Brahmer et al. Journal of Thoracic Oncology
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- (2010) Rebecca L Stone et al. LANCET ONCOLOGY
- Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
- (2010) Lucio Crinò et al. LANCET ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity
- (2010) G. Chong et al. Therapeutic Advances in Medical Oncology
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- (2009) P. Bono et al. ANNALS OF ONCOLOGY
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
- (2009) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy
- (2009) Yosuke Horita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bevacizumab Safety in Patients with Central Nervous System Metastases
- (2009) B. Besse et al. CLINICAL CANCER RESEARCH
- Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
- (2009) Konstantin J. Dedes et al. EUROPEAN JOURNAL OF CANCER
- Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
- (2009) James Cassidy et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases
- (2009) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab-associated gastrointestinal perforation
- (2009) Ian Chau et al. LANCET ONCOLOGY
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models
- (2009) K. Kolinsky et al. MOLECULAR CANCER THERAPEUTICS
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
- (2009) M. Kozloff et al. ONCOLOGIST
- First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma
- (2008) B. Melichar et al. ANNALS OF ONCOLOGY
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors
- (2008) Jian-Feng Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
- (2008) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
- (2007) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now